REG - GSK PLC - Notice of AGM

GSKAnnouncement

Today 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260325:nRSY0906Ya&default-theme=true

RNS Number : 0906Y  GSK PLC  25 March 2026

 

Issued: 25 March 2026, London UK

 

GSK plc Publication of Notice of Annual General Meeting 2026

 

 

 

The Company has today published on its website
(www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/
(http://www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/)
) the Notice of Annual General Meeting ('AGM') 2026 (the '2026 AGM Notice'),
which will be distributed to shareholders shortly.

 

The Company's AGM will be held on Wednesday 6 May 2026 at 2.30pm at the London
Marriott Hotel Grosvenor Square, Grosvenor Square, London, W1K 6JP and will
also be broadcast live for shareholders to join electronically. Full details
of how to join the meeting either in person or electronically are contained in
the 2026 AGM Notice and AGM Guide.

In compliance with Listing Rule 6.4.1R of the UK Financial Conduct Authority's
('FCA') Listing Rules, the following documents will be submitted to the FCA
and will, in due course, be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) :

 

·      2026 AGM Notice

·      Proxy Form for the AGM

·      The Company's Articles of Association marked up to show proposed
changes

 

 

 

V A Whyte

Company Secretary

 

25 March 2026

 

 

 

About GSK
GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2025.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAJAMMTMTMTBBF



            Copyright 2019 Regulatory News Service, all rights reserved